MediPal Holdings (7459) Q3 2026 earnings summary

Executive summary

• Consolidated net sales rose 3.7% year-over-year to ¥2,911.6 billion, driven by growth in Prescription Pharmaceutical, Cosmetics, Daily Necessities, OTC Pharmaceutical, MEDICEO, and PALTAC businesses.

• Operating profit decreased by 4.8% to ¥43.1 billion due to increased SG&A from business and human resource investments.

• Ordinary profit grew 8.1% to ¥61.3 billion, supported by increased non-operating income.

• Profit attributable to owners of parent increased 3.2% to ¥37.4 billion, supported by higher non-operating income and extraordinary items.

Financial highlights

• Gross profit increased 2.5% year-over-year to ¥199.0 billion, with a gross margin of 6.84%.

• SG&A expenses rose 4.7% to ¥155.8 billion, mainly due to business investment and higher logistics costs.

• Comprehensive income for the period was ¥54.4 billion, up 5.9% year-over-year.

• Total assets as of December 31, 2025, were ¥2,019.4 billion, up ¥194.4 billion from March 31, 2025.

• Net assets increased to ¥783.9 billion, with a net worth ratio of 31.8%.

Outlook and guidance

• Full-year net sales forecast is ¥3,785.0 billion (+3.1% year-over-year), with operating profit expected at ¥52.0 billion.

• Ordinary profit is projected at ¥69.0 billion (up 5.7%), and profit attributable to owners of parent at ¥34.5 billion (down 14.3%).

• Earnings per share forecast is ¥167.63, reflecting treasury stock acquisition and cancellation.

• Planned full-year dividend is ¥64.00 per share.

• Profit attributable to owners of parent has already exceeded the full-year forecast as of Q3.